UPCC 03820: A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of the study is to test the safety, anti-tumor activity, and the ability of an investigational drug called BMS-986179 plus nivolumab to block the protein CD73 from producing high amounts of a product known as adenosine which blocks the immune system from killing cancer cells. At our site we enroll subjects onto Part 2 of this study to test the dose and dose schedule that was previously identified. This study will be available to subjects with renal cell cancer (RCC).
Details
| Condition | Medical Research |
|---|---|
| Age | 99years or below |
| Clinical Study Identifier | TBD |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.